Xortx Therapeutics Stock Buy Hold or Sell Recommendation
| XRTX Stock | USD 3.05 0.12 3.79% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding XORTX Therapeutics is 'Strong Sell'. Macroaxis provides XORTX Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding XRTX positions. The advice algorithm takes into account all of XORTX Therapeutics' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting XORTX Therapeutics' buy or sell advice are summarized below:
Real Value 3.81 | Target Price 6.16 | Hype Value 2.67 | Market Value 3.05 | Naive Value 3.93 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell XORTX Therapeutics given historical horizon and risk tolerance towards XORTX Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for XORTX Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
XORTX |
Execute XORTX Therapeutics Buy or Sell Advice
The XORTX recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on XORTX Therapeutics. Macroaxis does not own or have any residual interests in XORTX Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute XORTX Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | OK | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
XORTX Therapeutics Trading Alerts and Improvement Suggestions
| XORTX Therapeutics is way too risky over 90 days horizon | |
| XORTX Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (6.71 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| XORTX Therapeutics currently holds about 13.42 M in cash with (8.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.03. | |
| XORTX Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: XORTX Announces Participation in Spring 2024 Investor Conferences - Yahoo Finance |
XORTX Therapeutics Returns Distribution Density
The distribution of XORTX Therapeutics' historical returns is an attempt to chart the uncertainty of XORTX Therapeutics' future price movements. The chart of the probability distribution of XORTX Therapeutics daily returns describes the distribution of returns around its average expected value. We use XORTX Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of XORTX Therapeutics returns is essential to provide solid investment advice for XORTX Therapeutics.
| Mean Return | 0.94 | Value At Risk | -10.07 | Potential Upside | 21.08 | Standard Deviation | 9.72 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of XORTX Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
XORTX Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as XORTX Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading XORTX Therapeutics backward and forwards among themselves. XORTX Therapeutics' institutional investor refers to the entity that pools money to purchase XORTX Therapeutics' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dekabank Deutsche Girozentrale | 2023-12-31 | 2.8 M | Advisor Group Holdings, Inc. | 2023-12-31 | 1.2 K | Royal Bank Of Canada | 2023-12-31 | 523 | Hartland & Co | 2023-12-31 | 277 | Citadel Advisors Llc | 2023-09-30 | 0.0 |
XORTX Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (201.4K) | 112.7K | 14.7M | (3.5M) | (2.8M) | (2.7M) | |
| Free Cash Flow | (256.6K) | (742.8K) | (4.8M) | (8.9M) | (8.8M) | (8.4M) | |
| Capital Expenditures | 7.0K | 14.4K | 31.2K | 44.2K | 51.9K | 31.4K | |
| Net Income | (629.6K) | (1.3M) | (1.3M) | (7.0M) | (6.7M) | (6.4M) | |
| End Period Cash Flow | 58.6K | 171.3K | 14.8M | 10.4M | 5.2M | 3.8M | |
| Depreciation | 19.9K | 20.4K | 14.0K | 55.5K | 135.2K | 142.0K | |
| Other Non Cash Items | 1.6K | (90.2K) | 58.8K | 3.7K | 3.3K | 3.2K | |
| Investments | (7.0K) | (14.4K) | (39.8K) | (44.2K) | (51.9K) | (54.5K) | |
| Change To Netincome | 62.0K | 173.5K | (3.1M) | (4.5M) | (4.1M) | (3.9M) |
XORTX Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to XORTX Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that XORTX Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a XORTX stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.91 | |
β | Beta against NYSE Composite | 0.30 | |
σ | Overall volatility | 9.93 | |
Ir | Information ratio | 0.09 |
XORTX Therapeutics Volatility Alert
XORTX Therapeutics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure XORTX Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact XORTX Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.XORTX Therapeutics Fundamentals Vs Peers
Comparing XORTX Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze XORTX Therapeutics' direct or indirect competition across all of the common fundamentals between XORTX Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as XORTX Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of XORTX Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing XORTX Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare XORTX Therapeutics to competition |
| Fundamentals | XORTX Therapeutics | Peer Average |
| Return On Equity | -0.37 | -0.31 |
| Return On Asset | -0.35 | -0.14 |
| Current Valuation | 5.4 M | 16.62 B |
| Shares Outstanding | 2.9 M | 571.82 M |
| Shares Owned By Insiders | 4.07 % | 10.09 % |
| Shares Owned By Institutions | 23.94 % | 39.21 % |
| Number Of Shares Shorted | 21.1 K | 4.71 M |
| Price To Earning | 170.67 X | 28.72 X |
| Price To Book | 1.60 X | 9.51 X |
| EBITDA | (4.88 M) | 3.9 B |
| Net Income | (6.71 M) | 570.98 M |
| Cash And Equivalents | 13.42 M | 2.7 B |
| Cash Per Share | 1.03 X | 5.01 X |
| Total Debt | 77.44 K | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 14.09 X | 2.16 X |
| Book Value Per Share | 2.32 X | 1.93 K |
| Cash Flow From Operations | (8.75 M) | 971.22 M |
| Short Ratio | 0.18 X | 4.00 X |
| Earnings Per Share | (3.60) X | 3.12 X |
| Price To Earnings To Growth | 9.08 X | 4.89 X |
| Target Price | 12.03 | |
| Number Of Employees | 2 | 18.84 K |
| Beta | -0.15 | -0.15 |
| Market Capitalization | 8.92 M | 19.03 B |
| Total Asset | 12.34 M | 29.47 B |
| Retained Earnings | (14.13 M) | 9.33 B |
| Working Capital | 9.36 M | 1.48 B |
| Current Asset | 341.74 M | 9.34 B |
| Current Liabilities | 109.37 M | 7.9 B |
| Net Asset | 12.34 M |
XORTX Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as XORTX . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About XORTX Therapeutics Buy or Sell Advice
When is the right time to buy or sell XORTX Therapeutics? Buying financial instruments such as XORTX Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 3.8M | 149.0K | 171.4K | 162.8K | Total Assets | 17.3M | 12.3M | 14.2M | 14.9M |
Use Investing Ideas to Build Portfolios
In addition to having XORTX Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Volatility ETFs Thematic Idea Now
Volatility ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Volatility ETFs theme has 28 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Volatility ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out XORTX Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for XORTX Stock analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is XORTX Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XORTX Therapeutics. If investors know XORTX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XORTX Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.35) | Return On Equity (0.37) |
The market value of XORTX Therapeutics is measured differently than its book value, which is the value of XORTX that is recorded on the company's balance sheet. Investors also form their own opinion of XORTX Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is XORTX Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XORTX Therapeutics' market value can be influenced by many factors that don't directly affect XORTX Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XORTX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if XORTX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XORTX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.